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We aimed to analyze the pre- and posttreatment serum asymmetric dimethylarginine (ADMA), nitrate (NO3), vitamin B12 and
homocysteine levels in pulmonary embolism (PTE) patients and to determine the prognostic value of these variables in predicting
chronicthromboembolicpulmonaryhypertension(CTEPH).Thisstudywasconductedin64patients.Thepatientswereclassiﬁed
into the two groups: patients with normal pulmonary artery pressure (PAP) (group I) and patients with high PAP with persistent
lung perfusion defects or who died at the end of 3 months of therapy (group II). We found statistically signiﬁcant diﬀerences
between two groups with respect to the partial oxygen pressure, the oxygen saturation, and the PAP, but there was no diﬀerence
between the two groups with respect to the pretreatment ADMA, NO3, or homocysteine levels. The vitamin B12 levels were higher
ingroupII.TheNO3 levelsincreasedandtheADMAandvitaminB12 levels decreasedwithtreatmentinbothgroups.Theseresults
suggest that these parameters are not predictive of the development of CTEPH.
1.Introduction
A pulmonary artery embolism is deﬁned as a partial
or complete occlusion of a pulmonary arterial branch.
Approximately 70% of cases are caused by pelvic or leg
thromboses [1, 2]. Precise ﬁgures for the incidence of
pulmonary embolism (PTE) are not available. The annual
incidence of diagnosed venous thromboembolism (VTE) is
150 to 200 cases per 100,000 population [3]. Considering
the unknown number of clinically silent embolisms and the
nonspeciﬁcclinicalpresentation,theactualdiseasefrequency
is underestimated.
PTE is a severe and potentially fatal disease when the
embolism is massive. CTEPH, which develops after the
obliteration of the pulmonary vascular bed by repeated
and organized PTE, is one of the less frequently seen forms
of PTE and is characterized by unexplained dyspnea and
a reduction in exercise capacity [4] .C T E P Hi sd e ﬁ n e da s
symptomatic pulmonary hypertension (mean pulmonary
artery pressure (mPAP) >25mmHg) with persistent lung
perfusion defects [5].
CTEPH is a life threatening and debilitating disease
aﬀecting up to 5% of survivors of PTE [6]. The disease is
underdiagnosed, and its true prevalence is still unclear. It
is characterized by intraluminal thrombus organization and
ﬁbrotic stenoses or complete obliteration of the pulmonary
arteries. Pulmonary embolism, either as single or recurrent
episode(s), is believed to be the initiating event, followed by
progressive vascular remodeling [7]. CTEPH is a common
variation of PTE [8]. Endothelial dysfunction, attributable
to the reduced bioavailability of endogenous vasodilator
substances such as NO, is believed to play an important
role in the pathogenesis of pulmonary hypertension [9, 10].
NO is synthesized in the endothelium from L-arginine by
NO synthase (NOS), which is present as either endothe-
lial NOS (eNOS) or inducible NOS (iNOS), representing
important vascular isoforms. The most abundant endoge-
nous NOS inhibitor is ADMA [11]. Homocysteine is also
associated with endothelial dysfunction [12]. Homocysteine
is a sulfhydryl amino acid derived from the metabolic
conversion of methionine. This conversion is dependent on
vitamins (folic acid, B12,a n dB 6) as cofactors or cosubstrates.2 Mediators of Inﬂammation
Severe hyperhomocysteinemia (homocystinuria), due to
inherited metabolic defects in homocysteine metabolism,
is associated with a very high risk of VTE, and treatment
with vitamins is associated with a dramatic decrease in the
VTE risk [13] .T h er e s u l t so fe a r l i e rs t u d i e sh a v es u g g e s t e d
that excess levels of homocysteine lead to increases in
ADMA levels and the impairment of endothelial function
[12, 14]. It has been hypothesized that the NO, ADMA,
and homocysteine levels may provide information about the
likelihood of the development of CTEPH in PTE patients.
Skoro-Sajer et al. found that increased ADMA plasma levels
were present in patients with CTEPH. ADMA levels were
correlated with the severity of pulmonary vascular disease,
and they decreased after pulmonary endarterectomy [15].
The purpose of our study was to analyze the pre-
and posttreatment serum ADMA, NO3, vitamin B12,a n d
homocysteine levels in PTE patients and to evaluate the
predictive value of the variables for development of CTEPH.
2.MaterialsandMethods
2.1. Subjects. The subjects of our study were selected among
patients who were admitted to the Zonguldak Karaelmas
University Hospital Pulmonary Clinic between March 1,
2009 and December 31, 2009. A total of 100 patients
who were diagnosed with PTE were included in the study.
The diagnosis of pulmonary embolism was conﬁrmed only
when computed tomography angiography (CTPA) showed
a pulmonary vascular ﬁlling defect or when ventilation-
perfusion (V/Q) scintigraphy showed at least two segmental
defects without ventilation defects. During the diagnosis
period,allthepatientsunderwentechocardiography,andthe
mean PAPs were measured. Posttreatment echocardiograms
were obtained in 50 surviving patients at the end of 3
months. The patients who did not experience a decrease in
PAP underwent V/Q scintigraphy to determine if CTEPH
had developed.
Patients receiving drugs aﬀecting the homocysteine level
(vitamin B6, vitamin B12, folic acid, folinic acid, or fenoﬁ-
brates) or drugs aﬀecting the ADMA level (L-arginine, ACE
inhibitors, metformin and thiazolidinediones, estrogens,
vitamin D, folic Acid, all-transretinoic acid, or fenoﬁbrates);
patients with end-stage liver disease, end-stage renal disease,
acute coronary syndrome, severe congestive heart failure,
Alzheimer’sdiseaseorpreeclampsia;patientsinhemorrhagic
shock were excluded from the study.
Echocardiography was performed in all patients during
the diagnosis period. Pulmonary hypertension was deﬁned
as mPAP >25mmHg. Patients’ ejection fractions (EF) were
measured, and the patients with advanced heart failure
(EF (%) < 40) were excluded from the study. None of
the patients were on anticoagulant therapy for any event
at the time of diagnosis. Patients received either low-
molecular-weight heparin or enoxaparin at a ﬁxed dose
per kilogram of body weight subcutaneously two times per
day or unfractionated heparin at an initial bolus dose of
80IU per kilogram followed by a continuous intravenous
infusion at an initial rate of 18IU per kilogram per hour.
The dose was subsequently adjusted so that the activated
partial thromboplastin time (aPTT) was two to three times
the control value in normal subjects. aPTTs were determined
six hours after the start of treatment and whenever a
subtherapeutic aPTT was measured after a dose adjustment.
Otherwise, the aPTT was tested daily. In each patient, oral
anticoagulant therapy was initiated between the ﬁrst and
third days of the initial heparin therapy and was continued
foratleastthreemonths.Thedosewasadjustedtoachievean
international normalized ratio (INR) of 2.0 to 3.0. Heparin
was stopped after 5 days of combined therapy with oral
anticoagulant drug when the INR exceeded 2.0. Three of the
patients with a diagnosis of acute massive embolism were
given heparin and an oral anticoagulant after thrombolytic
treatment (tissue plasminogen activator (tPA), 100mg over
2hours).
The patients were informed about the study, and the
study protocol was approved by our hospital’s ethics com-
mittee (date 03/19/2009 and meeting no. 2009/04).
2.2. Samples. At diagnosis and at the end of 3 months
of pulmonary embolism therapy, 20cc antecubital venous
blood was drawn from the patients to evaluate biochemical
parameters (e.g., the levels of folic acid, vitamin B12,
homocysteine, ADMA, and NO3).
2.3. Laboratory Investigations. Biochemical levels (folic acid,
vitamin B12) were measured by enzymatic techniques using
a DAX 72 autoanalyzer (Bayer Diagnostics Division, Tarry-
town, NY, USA). Sera in biochemistry and hemogram tubes
were separated by centrifugation in a cooling centrifuge at
3500 ×g for 10minutes for the ADMA, NO2, and homocys-
teineanalyses.TheywerealiquotedintoEppendorftubesand
stored at −80◦C for ADMA, NO2, and homocysteine mea-
surements. Homocysteine was evaluated using an ELX800
plaque reader with an axis shield diagnostic ELISA kit
(Dundee, UK), and the results were recorded. Homocysteine
levels of 5–15mg/dl were considered normal. For vitamin
B12,valuesof19–946pg/mLwereconsiderednormal,andfor
folic acid, values of 4.6–18.7ng/mL were considered normal.
Serum ADMA levels were evaluated with commercial ELISA
kits (Immundiagnostik AG, Bensheim, Germany) using an
ELX800 ELISA plaque reader instrument. The results were
expressed as µmol/L. Because the half-life of NO is very short
(10–30sec.)andmeasurementisdiﬃcultbecauseitisrapidly
oxidizedandconvertedintonitrite(NO2)andnitrate(NO3),
total nitrate levels were used as a reﬂection of NO levels.
The total serum nitrate measurement was performed by the
cadmium reduction method [16].
3.StatisticalAnalysis
Statistical analysis was done using the SPSS USA (version
13.0) program. The compliance of numerical variables to
a normal distribution was assessed using the Kolmogorov-
Smirnov test. Deﬁnitive statistics were expressed as the mean
±standarddeviationfornormallydistributeddataandasthe
number and percentage for categorical variables. Relation-
ships between categorical variables were assessed by the Chi-
Square and Fisher’s Exact tests. Nonparametric data wereMediators of Inﬂammation 3
Table 1: Parameters at the beginning of the treatment in Group I and Group II.
Group I
∗ Group II
∗∗ P
n = 40 n = 24
Age 65.7 ± 13.4 70.9 ± 14.1 0.148
Sex (female/male) 20/20 13/11 0.949
Partial oxygen pressure (mmHg) 62.1 ± 7.4 54.1 ± 9.3 <0.001∗
Oxygen saturation (%) 92.8 ± 3.2 86.8 ± 6.2 <0.001∗
Mean PAP (mmHg) 39.0 ± 9.6 50.8 ± 21.8 0.008∗
∗Group I:Patients with normal pulmonary artery pressure at the end of three months of treatment.
∗∗Group II:Patients with high pulmonary artery pressure or who had died at the end of three months of treatment.
Table 2: Pretreatment ADMA, NO3, homocysteine, and vitamin B12 levels in patients with normal pulmonary pressure (Group I) and
patients with high pulmonary pressure or who died (Group II).
Group I Group II P
n = 40 n = 24
ADMA (µmol/L) 0.63 ± 0.19 0.58 ± 0.26 0.399
NO3 (µmol/L) 33.8 ± 2.4 33.8 ± 2.1 0.978
Homocysteine (mg/dl) 19.2 ± 8.8 17.1 ± 8.1 0.358
Vitamin B12 (pg/dl) 380.5 ± 244.7 649.3 ± 463.9 0.003∗
compared with the Mann-Whitney U test. Comparisons of
pre- and posttreatment values were performed using the
Wilcoxon test. Linear relationships between two variables
were assessed using the Pearson (for parametric data) and
Spearman (for nonparametric data) correlation analyses.
Results were evaluated using 95% conﬁdence intervals, and
P<0.05 was considered statistically signiﬁcant.
4. Results
Of 100 patients with PTE diagnosed between March 2009
and December 2009, 36 patients discontinued the study
during the followup. Therefore, 64 patients were included in
the study. Fifteen patients died during treatment period. The
baseline patient characteristics and hemodynamic param-
eters are summarized in Table 1. Of these 64 patients, 59
(59%) were nonsmokers, 39 (39%) were exsmokers, and 2
(2%) were active smokers. V/Q scintigraphy was performed
in 10 of the 50 surviving patients with an elevated PAP
determined by control echocardiography at the end of three
months of treatment. Perfusion defects were detected in 9
(14%) of the 64 patients, and these patients were considered
CTEPH candidates. The patients were classiﬁed into two
groups: patients with a normal PAP (group I) and patients
with a high PAP and/or a moderate to high probability based
on V/Q scintigraphy or who died before the end of the 3
months of therapy (group II). Heart failure, renal failure,
COPD (chronic obstructive pulmonary disease), and prior
malignancy were present in 10 (10%), 5 (5%), 25 (25%), and
13(13%)ofpatients,respectively.Whenthetwogroupswere
compared, statistically signiﬁcant diﬀerences were detected
with respect to the partial oxygen pressure (P<0.001), the
oxygen saturation (P<0.001), and the PAP (P = 0.008)
(Table 1). There was no statistically signiﬁcant diﬀerence
between the two groups with respect to comorbidities.
Moreover, there were no statistically signiﬁcant diﬀerences
between the two groups in terms of pretreatment ADMA,
NO3, or homocysteine levels (P>0.05). However, vitamin
B12 levels were higher in group II (patients with high
PAP or who died) compared to group I (patients with
normal PAP); this diﬀerence was statistically signiﬁcant
(P = 0.003) (Table 2). The posttreatment ADMA, NO3,
homocysteine, and vitamin B12 levels were evaluated at
the end of the 3 months of therapy. We found that after
treatment, the NO3 levels increased (P<0.001) from initial
low levels, and the ADMA (P<0.001) and vitamin B12
levels decreased signiﬁcantly (P<0.006) from initial high
levels; the homocysteine levels did not change signiﬁcantly
(Table 3). At the beginning of the treatment period, the
patientswereclassiﬁedintofourcategoriesaccordingtotheir
arterial pO2 levels as normoxic (n = 1), mildly hypoxic
(n = 34), moderately hypoxic (n = 27), or severely hypoxic
(n = 2). When mildly and moderately hypoxic patients
were compared to severely hypoxic patients in terms of
the pretreatment ADMA, NO3, homocysteine, and mPAP
levels, only the mPAP was found to be signiﬁcantly diﬀerent
between the two groups (P = 0.009) (Table 4). High serum
homocysteine levels were found in 58% of our patients, and
the pre- and posttreatment serum homocysteine and ADMA
levels were found to be signiﬁcantly correlated (r:0.300,
P:0.016 and r:0.293, P:0.039, resp.).
5. Discussion
The major novel ﬁndings of the present study are as follows
(1) In the 4th month of treatment, 14% of acute pulmonary
embolism patients still had high PAPs and perfusion defects.
(2) Initial high ADMA levels decreased after the treatment,4 Mediators of Inﬂammation
Table 3: ADMA, NO3, homocysteine, and vitamin B12 levels in patients (before and after 3 months of anticoagulant therapy).
Before therapy After 3 months of therapy
n = 50 n = 50
ADMA (µmol/L) 0.64 ± 0.19 0.49 ± 0.16 <0.001∗
NO3 (µmol/L) 33.7 ± 2.3 41.5 ± 4.4 <0.001∗
Homocysteine (mg/dl) 18.4 ± 8.3 19.3 ± 9.9 0.519
Vitamin B12 (pg/dl) 443.3 ± 300.7 355.6 ± 215.9 0.006∗
Table 4: Pretreatment ADMA, NO3, homocysteine and mean PAP levels according to the patients’ hypoxia levels.
Level hypoxia n Mean ± standard deviation P
ADMA (µmol/L) Mild 34 0.62 ± 0.22 0.709
Moderate-severe 29 0.60 ± 0.23
NO3 (µmol/L) Mild 34 33.8 ± 2.1 0.920
Moderate-severe 29 33.8 ± 2.4
Homocysteine (mg/dl) Mild 34 18.6 ± 9.2 0.964
Moderate-severe 29 18.5 ± 7.9
Mean PAP (mmHg) Mild 34 38.1 ± 10.9 0.009
∗
Moderate-severe 29 49.3 ± 19.4
whereas NO3 levels increased. Additionally, the vitamin B12
levels decreased with anticoagulant treatment. (3) Pretreat-
ment hypoxia was found to be a poor prognostic factor
for PTE. (4) In the poor prognosis group, the vitamin B12
levels were high, but no statistically signiﬁcant diﬀerence was
found between the ADMA, NO3, and homocysteine levels.
There has recently been increasing interest in asymmet-
ric dimethylarginine (ADMA) as a marker and potential
mediator of endothelial dysfunction in pulmonary vascular
disease patients and as a potent competitive inhibitor of
NOS [17]. ADMA is derived from the catabolism of proteins
containing methylated arginine residues. Higher ADMA
concentrations have been measured in many cardiovascular
and metabolic diseases, such as coronary artery disease,
congestive heart failure, peripheral arterial occlusive disease,
hypercholesterolemia, hypertension, and diabetes mellitus
[18, 19]. ADMA has not been measured previously in acute
pulmonary embolism patients. In our study, there were no
statistically signiﬁcant diﬀerences between the two groups
with respect to the pretreatment ADMA and NO3 levels. In
both groups, the NO3 levels increased, and the ADMA and
vitamin B12 levels decreased with treatment.
It is not known clearly how the treatment acts on the
ADMA and NO levels. It was concluded that these eﬀects
might be the results of compensatory mechanisms related
to improvement in hypoxia and/or prolongation of period.
Changes in the vessel wall and the coagulation system
and chronic hypoxia are of value in predicting CTEPH
development [20–22]. Fifteen of our patients died during
treatment. We observed that 71% of cases in group II had
moderate to severe hypoxia. We concluded that persistent
high PAP and hypoxemia, compared with pretreatment
values, were found to be signiﬁcant parameters predicting
poor prognosis.
CTEPH was recently documented to complicate 3.8%
of acute pulmonary embolic events [3, 4]. However, there
may be many unreported cases, so the actual number
of cases may be higher. At the end of three months of
treatment and at the 12-month followup, 9% and 5% of
acute pulmonary embolism patients, respectively, showed
high PAP and persistent perfusion defect in our study.
ADMA has been evaluated in several diﬀerent classes
of pulmonary hypertension. Plasma levels were found to
be signiﬁcantly higher in idiopathic pulmonary arterial
hypertension patients than in healthy matched controls [23].
In a recent study of 135 patients diagnosed with CTEPH,
the plasma ADMA levels were measured at the time of
right heart catheterization and was remeasured in patients
who underwent pulmonary endarterectomy. The ADMA
level was signiﬁcantly elevated in patients compared with
controls [15]. However, in our study, we could not ﬁnd
any signiﬁcant diﬀerence in the plasma levels of NO3 and
ADMA with respect to mPAP. The variable conclusions
of the published studies to date seem to be related to
comparing the ADMA levels in the disease state with healthy
controls. Similar to our study, other authors have reported
decreased levels of ADMA after treatment (endarterectomy).
In addition, the measurement method of ADMA may vary.
One of the reasons could be the use of the more sensitive
high-performance liquid chromatography (HPLC) analysis
method by other authors instead of the ELISA method that
was used. In recent years, ELISA has been reported to be
compatiblewithHPLC,butmanystudieshavedemonstrated
that the HPLC method has better sensitivity and selectivity
[24].
Ithasbeenreportedthatelevatedhomocysteinelevelsare
associated with elevated ADMA levels. Both homocysteine
and ADMA are thought to mediate their adverse vascular
eﬀects by impairing endothelial nitric oxide-dependent
functions. Previous studies have shown that serum ADMA
levels were positively correlated with serum homocysteine
levels, as shown in our study [25, 26]. Our study showed thatMediators of Inﬂammation 5
the pre- and posttreatment serum homocysteine and ADMA
levels were signiﬁcantly correlated.
There is a relationship among increased plasma homo-
cysteine, folic acid, and vitamin B12 levels and premature
arterial disease [12, 13]. B¨ oger et al. [12]o b s e r v e da
correlation between plasma ADMA and homocysteine levels
in monkeys with hyperhomocysteinemia. Folic acid, vitamin
B6,a n dv i t a m i nB 12 levels are the signiﬁcant determinants
of homocysteine levels [27]. Serum homocysteine levels were
high in 58% of our patients. We found high B12 vitamin
levels in the poor prognosis group, and the serum levels were
decreased after treatment.
In conclusion, the lack of a diﬀerence in the pretreatment
ADMA and NO3 levels between patients with normal and
high PAPs, together with the signiﬁcant decrease in the
ADMA level and the increase in the NO3 level after the
treatment, suggests that these parameters are not predictive
of the development of CTEPH.
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